Income Statement Arecor Therapeutics plc
Equities
AREC
GB00BMWLM973
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.00 GBX | 0.00% | -1.84% | -56.16% |
09-11 | Arecor Therapeutics plc Presents Positive Data from Phase I Clinical Trial of Ultra-Concentrated, Ultra-Rapid Acting Insulins | CI |
07-23 | Arecor Therapeutics Completes Retail Offer | MT |
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 1.89M | 1.7M | 1.16M | 2.4M | 4.57M | |
Total Revenues | 1.89M | 1.7M | 1.16M | 2.4M | 4.57M | |
Gross Profit | 1.89M | 1.7M | 1.16M | 2.4M | 4.57M | |
Selling General & Admin Expenses, Total | 1.61M | 1.64M | 2.39M | 5.38M | 8.91M | |
R&D Expenses | 3.56M | 3.94M | 5.39M | 8.61M | 5.98M | |
Other Operating Expenses | -592K | -452K | -640K | -1.13M | -1.14M | |
Other Operating Expenses, Total | 4.58M | 5.13M | 7.14M | 12.86M | 13.75M | |
Operating Income | -2.69M | -3.43M | -5.98M | -10.46M | -9.18M | |
Interest Expense, Total | -13.07K | -82K | -22K | -26K | -15K | |
Interest And Investment Income | 9.41K | 2.98K | 1K | 109K | 284K | |
Net Interest Expenses | -3.66K | -79.02K | -21K | 83K | 269K | |
Other Non Operating Income (Expenses) | - | -5.29K | - | 5K | 5K | |
EBT, Excl. Unusual Items | -2.69M | -3.51M | -6M | -10.37M | -8.9M | |
Other Unusual Items | - | - | -947K | -171K | - | |
EBT, Incl. Unusual Items | -2.69M | -3.51M | -6.94M | -10.54M | -8.9M | |
Income Tax Expense | -502K | -760K | -776K | -1.28M | -347K | |
Earnings From Continuing Operations | -2.19M | -2.75M | -6.17M | -9.26M | -8.55M | |
Net Income to Company | -2.19M | -2.75M | -6.17M | -9.26M | -8.55M | |
Net Income - (IS) | -2.19M | -2.75M | -6.17M | -9.26M | -8.55M | |
Net Income to Common Incl Extra Items | -2.19M | -2.75M | -6.17M | -9.26M | -8.55M | |
Net Income to Common Excl. Extra Items | -2.19M | -2.75M | -6.17M | -9.26M | -8.55M | |
Per Share Items | ||||||
Net EPS - Basic | -0.14 | -0.17 | -0.27 | -0.32 | -0.28 | |
Basic EPS - Continuing Operations | -0.14 | -0.17 | -0.27 | -0.32 | -0.28 | |
Basic Weighted Average Shares Outstanding | 15.77M | 16.25M | 23.03M | 28.94M | 30.62M | |
Net EPS - Diluted | -0.14 | -0.17 | -0.27 | -0.32 | -0.28 | |
Diluted EPS - Continuing Operations | -0.14 | -0.17 | -0.27 | -0.32 | -0.28 | |
Diluted Weighted Average Shares Outstanding | 15.77M | 16.25M | 23.03M | 28.94M | 30.62M | |
Normalized Basic EPS | -0.11 | -0.14 | -0.16 | -0.22 | -0.18 | |
Normalized Diluted EPS | -0.11 | -0.14 | -0.16 | -0.22 | -0.18 | |
Supplemental Items | ||||||
EBITDA | -2.61M | -3.34M | -5.9M | -10.26M | -8.88M | |
EBITA | -2.68M | -3.42M | -5.97M | -10.37M | -9.08M | |
EBIT | -2.69M | -3.43M | -5.98M | -10.46M | -9.18M | |
EBITDAR | - | - | - | - | -8.44M | |
Effective Tax Rate - (Ratio) | 18.66 | 21.64 | 11.17 | 12.16 | 3.9 | |
Total Current Taxes | -502K | -760K | -776K | - | - | |
Normalized Net Income | -1.68M | -2.2M | -3.75M | -6.48M | -5.56M | |
Interest on Long-Term Debt | 7.62K | 17.98K | 22K | 18K | 15K | |
Supplemental Operating Expense Items | ||||||
General and Administrative Expenses | 1.61M | 1.64M | 2.39M | - | - | |
Research And Development Expense From Footnotes | 3.56M | 3.94M | 5.39M | 8.61M | 5.98M | |
Net Rental Expense, Total | - | - | - | - | 436K | |
Imputed Operating Lease Interest Expense | - | - | - | - | 167K | |
Imputed Operating Lease Depreciation | - | - | - | - | 269K | |
Stock-Based Comp., R&D Exp. (Total) | - | - | - | - | 156K | |
Stock-Based Comp., Other (Total) | 460K | 318K | 484K | 503K | 483K | |
Total Stock-Based Compensation | 460K | 318K | 484K | 503K | 639K |